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Human cytomegalovirus (HCMV) can cause debilitating, some- 
times fatal, opportunistic infections in congenitally infected 
infants and in immunodeficient individuals such as patients with 
the acquired immunodeficiency syndrome (AIDS). Molecular 
mechanisms that determine cell type specificity of HCMV in- 
fection and latency are poorly understood. We recently de- 
scribed a transgenic mouse model for analysis of HCMV major 
immediate-early (IE) promoter regulation and showed that sites 
of IE promoter activity during murine embryogenesis correlate 
with known target tissues of congenital HCMV infection in 
human fetuses (Koedood et al., 1995). Among various permis- 
sive human tissues, the brain is a site where HCMV infections 
can be devastating. Here, we have used immunohistochemical 
double-labeling analysis to identify specific cell types with 
HCMV-IE promoter activity in brains of transgenic mice at 
several postnatal stages. IE promoter activity was restricted to 
some endothelial cells, ependymal cells, choroid plexus epithe- 
lia, and neurons at discrete locations in the forebrain, brain- 
stem, and cerebellum. Endothelial cells and neurons with ac- 
tivity were proportionately more abundant in neonatal than in 
adult brains. Although the IE promoter was normally silent in 
most astrocytes, activity was strongly induced in reactive as- 
trocytes in response to a neocortical stab lesion. The findings 
support a model, consistent with clinical literature on HCMV 
encephalitis, whereby tissue damage and gliosis caused by 
HCMV infection of endothelial and ependymal cells progres- 
sively renders adjacent permissive neurons and reactive astro- 
cytes accessible to infection. This transgenic model system 
should facilitate identification of factors that regulate the HCMV 
IE promoter with regard to infection permissivity and reactiva- 
tion from latency. 
Key words: HCMV major immediate-early promoter; brain- 
specific transcription; viral pathogenesis; encephalitis; congen- 
ital HCMV infection; AIDS; blood- brain barrier; astrocytes; 
gliosis 
Human cytomegalovirus (HCMV), a common herpes virus, estab- 
lishes permanent residence in the host after primary infection, 
and viral replication can be periodically reactivated (Alford and 
Britt, 1990). Although HCMV rarely causes symptomatic disease 
in healthy human hosts, when immune mechanisms to neutralize 
and clear virus from the bloodstream are impaired, opportunistic 
HCMV infections increase in virulence and persistence. HCMV 
can be potentially life-threatening in immunodeficient patients 
and congenitally infected fetuses and infants (Bale, 1984; Klatt 
and Shibata, 1988; Huang and Kowalik, 1993; Vinters and Fer- 
reiro, 1993; Wiley and Nelson, 1993). Congenital HCMV infec- 
tion is the most frequent cause of prenatal injury to the CNS and 
can result in mental retardation, para- and quadriplegia, spastic- 
ity, sensorineural hearing deficits, optic atrophy, and seizure dis- 
orders (Saigal et al., 1982; Bale, 1984; Perlman and Argyle, 1992). 
HCMV is frequently associated with morbidity and mortality in 
immunosuppressed bone marrow or organ transplantation pa- 
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tients, cancer patients receiving chemotherapy, and patients with 
AIDS. HCMV is the most common opportunistic viral agent in 
AIDS patients and has the essential features of a cofactor in the 
progression from human immunodeficiency virus (HIV) infection 
to AIDS (Huang and Kowalik, 1993). HCMV infections of the 
CNS can cause necrotizing encephalitis and ependymitis and, in 
AIDS patients, can result in AIDS dementia complex complicated 
by cytomegalovirus encephalopathy, a syndrome distinguished by 
HCMV viremia, intra-blood-brain barrier HCMV antibody pro- 
duction, seizures, coma, and rapid demise (Fiala et al., 1993). 
Approximately half of AIDS patients show widespread HCMV 
infection at autopsy, with ~20% of these demonstrating CNS 
involvement (Klatt and Shibata, 1988). This frequency is similar to 
the 25% frequency of CNS involvement observed for preterm 
infants with lethal congenital HCMV infections (Perlman and 
Argyle, 1992). 
Molecular mechanisms that determine cellular permissivity, 
reactivation, and progressive infection by HCMV are poorly de- 
fined. Cell type-specific differences in HCMV immediate-early 
(IE) transcription are suspected to underlie differences in infec- 
tion permissivity, because this first phase of viral gene expression 
is dependent on host cell transcription factors (for review, see 
Ghazal and Nelson, 1993). However, analyses of IE promoter 
segments in gene transfection experiments with cultured cells 
have largely failed to confirm this hypothesis; the major IE pro- 
moter activates high levels of transcription in most cultured cell 
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types, including many that are nonpermissive for HCMV infec- 
tion. We recently described a transgenic mouse model system for 
studying HCMV major IE promoter regulation in viva (Koedood 
et al., 1995). In the present report, we have used this transgenic 
model to analyze cell type-specific IE promoter activity in the 
neonatal and adult brain. The results extend our previously re- 
ported correlation between IE promoter specificity in murine 
tissues and known target cell types of HCMV infection in humans, 
and provide strong evidence that the IE promoter is a major 
determinant of cellular permissivity for HCMV infection. In ad- 
dition, changes in IE promoter activity in the brain during devel- 
opment and during experimentally induced gliosis demonstrate 
how differentiation cues and tissue damage may play important 
roles in HCMV infection permissivity and pathogenesis in viva. 
MATERIALS AND METHODS 
Generution of trunsgenic mice. Transgenic mouse lines HCMV-1 and 
HCMV-2 carrying IacZ genes linked to the HCMV major IE enhancer/ 
promoter (-524 to +13 segment; hereafter referred to as the IE pro- 
motcr) were generated as described previously (Koedood et al., 1905). 
Tissueprepnrtrtion. Transgcne expression in brain cryosections of trans- 
genie (hemirygous) and nontransgenic littermates of HCMV-IE-IacZ 
transgenic mouse lines HCMV-I and HCMV-2 was analyzed by 
P-galactosidase (P-Cal) staining and by double immunofluorcscence 
staining using antibodies against P-Gal and various ccl1 type-specific 
markers. Mice wcrc deeply anesthetized with chloral hydrate (400 mgikg, 
i.p.) and perfused through the ascending aorta with 4% paraformalde- 
hyde in 0.15 M phosphate buffer, pH 7.4. Brains were removed immcdi- 
atcly after perfusion; post-fixed in the same tixativc for 3 hr, and stored 
overnight in 10% dimethvlsulfoxidc in PBS for crvonrotection (Fritschv cl , . 
al., 1994). Sections (40 km) wcrc cut from frozen blocks with a sliding 
microtomc and collected in PBS. 
p-&l s/uini~ Free-floating sections were washed 3 times for 5 min in 
PBS and incubated for 4 hr at 30°C in P-Gal stain solution with Bluo-Gal 
substrate (Gibco, Gaithcraburg, MD) prepared as described previously 
(Koedood ct al., 1095). The stained sections were washed 5 min in PBS, 
transferred briefly through dHzO, and mounted onto gelatin-coated 
slides, air-dried, post-fixed 5 min in 4% paraformaldehydc in PBS, and 
washed 5 min in PBS before countcrstaining with neutral red and mount- 
ing coverslips out of xylcne. For whole-mount staining of the leptome- 
ningcs, brains from perfused neonatal mice were bisected sagittally, 
washed 3 times for 20 min in PBS, and stained 4 hr at 30°C in P-Gal stain 
solution. They were then washed 15 min in PBS and post-fixed overnight 
in 4% paraformaldehydc in PBS before photography. The P-Gal activity 
was detected primarily in cell nuclei, attributable to the fusion of a 
nuclear localization signal in frame with the 1ucZ transgene used to 
prepare thcsc transgcnic mice. 
Immunoperoxidase staining. Free-floating sections were incubated over- 
night in primary antibody (rabbit anti-P-Gal Nr. 0631-0002, Cappel, 
West Chester, PA) diluted 15000 in PBS containing 2% normal strum 
and 0.2% Triton X-100, and then processed for the avidin-biotin-per- 
oxidase method of Hsu ct al. (1981) according to the specifications of the 
manufacturer (Vectastain Elite kits, Vector Laboratorics, Burlingame, 
CA), using diaminobcnzidinc hydrochloride as chromogen. Stained sec- 
tions were mounted on gelatin-coated slides, air-dried, dehydrated in 
ascending series of ethanol, and coverslipped out of xylene. 
Immunqfluorescence r/aining. Colocalization of P-Gal-positive nuclei 
with neuronal markers [microtubule-associated protein 2 (MAP-2) (Ma- 
tus et al., 1981) and GABA, rcccptor p2,3 subunits (Richards et al., 
1987)] and with astroglial markers [glial fibrillary acid protein (GFAP) 
(Bignami et al., 1980) and calcium-binding protcin SIOOP (Boycs et al., 
19X6)] were analyzed by double immunotluoresccnce staining. For this 
purpose, sections were incubated overnight with a mixture of primary 
antibodies (e.g., P-Gal and MAP-2) diluted in PBS containing 2% normal 
serum and 0.2% Triton X-100, washed three times with PBS, and incu- 
bated for 30 min with secondary antibodies coupled either to dichloro- 
triazinylaminofluorescein (1:lOO) or carboxymethylindocyanine (Cy3) (1: 
200; Jackson Immunoresearch, West Grove, PA). Selectivity was ensured 
by using primary antibodies raised in different species. Controls for 
specificity were performed by omitting one of the primary antibodies 
during the overnight incubation. The sections were then mounted on 
gelatin-coated glass slides, air-dried, covcrslipped with buffered glycerol, 
and analyzed by confocal laser microscopy (Leica TCS 4D, Nussloch, 
Germany). 
Cortictrl lesion. A stab lesion was made unilaterally under stereotaxic 
control in the frontal cortex of transgenic mice and nontransgenic control 
littermates. The mice were deeply anesthetized by intraperitoneal admin- 
istration of ketamin (100 mg/kg) and xylacin (16 mg/kg) before the 
operation. Lesioncd mice and unlesioned controls were perfused at 
various time points (0,6, and 12 hr, and 1,3, and 6 d), and the brains were 
processed for immunohistochemistry with P-Gal and GFAP antibodies as 
described above. All animal procedures were performed according to the 
Swiss animal protection laws and the principles of laboratory animal care 
(National Institutes of Health publ. No 85-23). 
RESULTS 
Identification of brain regions and cell types with 
HCMV IE promoter activity 
The cell type-specific activity of the HCMV IE promoter was 
analyzed by P-Gal staining and immunohistochemical analysis of 
brain tissue from neonatal and older mice of transgenic lines 
HCMV-1 (Figs. 1,2) and HCMV-2 (latter not shown) carrying 
ZucZ genes driven by the IE promoter -524 to + 13 segment. The 
qualitative similarity in IE promoter specificity in these two lines 
during embryogenesis has been described previously (Koedood et 
al., 1995). In the brain, IE promoter activity was observed in 
nearly identical sites and cell types in the two transgenic lines, but, 
as in embryonic tissues, HCMV-1 line mice yielded consistently 
stronger expression compared with HCMV-2 line mice in almost 
all the sites of activity. One activity site in HCMV-1 mice that did 
not appear in HCMV-2 mice was the thalamus. This difference 
was also apparent during embryogcncsis, with HCMV-1 embryos 
showing unique activity in the ventral midbrainidiencephalon be- 
ginning at 10.5 d postcoitus (Koedood et al., 1995). The otherwise 
high concordance between the two lines confirms that, with the 
exception of the thalamus, the 1ucZ expression patterns observed 
with these mice are bona fide representations of the innate spec- 
ificity of this IE promoter segment in viva. 
Anti-P-Gal immunostaining of brain sections from both new- 
born (postnatal day 0, or PO) (Fig. 1A) and 5-week-old HCMV-1 
mice (Fig. 1B) revealed IE promoter activity in non-neuronal 
structures that included the leptomeninges (Fig. lC,D), ependy- 
mal, and choroid plexus epithelia (Fig. lF), and in several discrete 
neuronal populations in the forebrain, brainstem, and cerebellum 
(Fig. l/l&E). Expression in presumptive endothelial cells (Fig. 
1G) was widespread in neonatal brains (Fig. L4,C), particularly in 
the pia mater (Fig. lC,D), but was less evident in sections of more 
mature mice (Fig. IB). 
Immunofluorescent double-labeling analysis with antibodies 
against p-Gal and various cell type-specific markers indicated that 
in most locations, nonendothelial cells with IE promoter activity 
were predominantly neurons rather than astrocytes (Fig. 2A-C). 
GFAP- or SlOOP-positive astrocytes with P-Gal immunoreactivity 
wcrc rarely seen (Fig. 20), and glial cells in white matter (oligo- 
dendrocytes) were always P-Gal-negative (data not shown). The 
regional distribution of neurons with IE promoter activity was 
similar at different stages of postnatal development, but, as was 
also the case for endothelial cells, the proportion of positive 
neurons was significantly higher in newborn mice than in older 
mice (in Fig. 1, compare PO section in A with 5 week section in B). 
The distribution of brain nuclei with positive neurons is summa- 
rized in Table 1. In mice at 5 weeks of age, a prominent labeling 
of neurons was observed in the olfactory bulb, hippocampus CA1 
and CA3 subfields, deep cortical layers, thalamus, granule cell 
layer and deep nuclei of the cerebellum, and several brainstem 
structures (Fig. 1B). The proportion of labeled neurons varied 
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Figure 1. Distribution of cells with HCMV IE promoter activity in the brain of neonatal (PO, A and E; P2, C and D) and 5 week-old mice (B, F, G), as 
visualized by P-Gal histochemical staining (C, 0, G) or by immunoperoxidase staining with anti-P-Gal antibodies (A, B, E, F). High densities of positive 
nuclei are evident in specific brain regions (arrowheads in A and B), especially at PO. The labeling is also prominent in the leptomeninges, as seen in a 
P2 whole-brain mount (C) or in an isolated fragment of pia-arachnoid (D), where positive nuclei are clearly associated with blood vessels. On the cellular 
level, positive nuclei are evident, for instance, in neurons of deep cortical layers (E); in the choroid plexus and ependyma (F; the U~WVS point to weakly 
positive ependymal cell nuclei); and in presumptive endothelial cells lining a brain microvessel (G). Abbreviations: 5, motor nucleus of the trigeminal 
nerve; 7, facial motor nucleus; cp, cortical plate; CPU, caudate-putamen; IC, inferior colliculus; T/z, thalamus; V, cerebral cortex layer V; Vr, cortical layer 
VI. Scale bars: A-C, 1 mm; D, 250 pm; E, 50 hrn; F, 20 pm; G, 10 Frn. 
greatly among the various brain regions, and there was consider- 
able regional selectivity in their distribution. Apart from the 
thalamus, where IE promoter activity was not independently 
confirmed in HCMV-2 mice, the highest proportions of labeled 
neurons were seen in brainstem motor nuclei and in certain 
sensory afferent nuclei, such as the cochlear and vestibular nuclei. 
In other nuclei, such as the spinal trigeminal nucleus, only a few 
scattered positive neurons could be detected. 
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Figure 2. Vidt ElG+=G4m!!m mages rom con oca aser mrcroscopy illus ratmg ce regions. 
Antibodies against the neuron-specific markers MAP-2 (A, C) and GABA, receptor p2,3 sub1 inits (B) and against the astrocyte-specific marker GFAP 
(D-G) were combined with P-Gal antibodies in double immunofluorescence staining experiments to identify cell types exhibiting HCMV IE promoter 
activity. The images corresponding to each antigen were digitized simultaneously using different filter combinations, color-coded, and superimposed. In 
all cases, the P-Gal immunofluorescence is shown in red, whereas the neuronal or astrocytic marker immunofluorescence is shown ingreen. The selective 
neuronal localization of HCMV IE promoter activity in normal adult brain is depicted for the hippocampus CA3 subfield (A), cerebellum (B), and deep 
cortical layers (C). The armwhead in A points to a presumptive endothelial cell nuclei (flattened profile). The lack of expression in astrocytes is illustrated 
for the CA1 subfield of the hippocampus (D), where all p-Gal-positive nuclei are located in the pyramidal cell layer (py). By contrast, prominent HCMV 
IE promoter (P-Gal-positive) activity is present in GFAP-positive reactive astrocytes 6 d after a stab lesion in frontal cortex, as shown in E-G. E and F 
depict the colocalization of P-Gal and GFAP immunoreactivity in cortical reactive astrocytes in the vicinity of the lesion (F) and in the ipsilateral parietal 
cortex (E). In certain cases, the P-Gal staining was so intense that it spread into the finest processes of the astrocyte (awow in F). Amwheads in E point 
to presumptive neuronal nuclei (larger, round), which are also present in the control hemisphere. G depicts double-labeled astrocytes in the 
caudate-putamen ipsilaterally to the lesion. In both normal and lesioned brains, microglia were P-Gal-negative (data not shown). gr, Granule cell layer 
of the cerebellum; PC, Purkinje cell layer; py, pyramidal cell layer of the hippocampus; wm, white matter. Scale bars, 20 pm. 
wm 
Fritschy et al. . HCMV Immediate-Early Promoter Specificity in the Brain J. Neurosci., April 1, 1996, 16(7):2275-2282 2279 
Table 1. Regional distribution of neurons with HCMV IE promoter activity (HCMV-1 line) 
Region 
Positive 
neurons Region 
Positive 
neurons 
Olfactory bulb 
Glomerular layer 
Mitral cells 
Granule cells 
Cerebral cortex 
Layers I-IV 
Layer V 
Layer VI, caudal 
Layer VI, rostra1 
Entorhinal cortex 
Subiculum 
Hippocampal formation 
CA1 subfield 
CA3 subfield 
Dentate gyros 
Amygdala 
Lateral nucleus 
Central nucleus 
Basolateral nucleus 
Basal ganglia 
Septal nuclei 
Caudate-putamen 
Pallidurn 
Olfactory tuber& 
Substantia nigra 
Thalamus 
Ventroposterior nucleus 
Lateral geniculate nucleus 
Ventrolateral nucleus 
Anterodorsal nucleus 
Intralaminar nuclei 
Mediodorsal nucleus 
Reticular nucleus 
Subthalamic area 
** 
* 
** 
* 
*** 
** 
- 
** 
- 
- 
*** 
*** 
** 
:a** 
* 
* 
- 
Pretectal area 
Hypothalamus 
Medial preoptic area 
Brainstem 
Tectum 
Red nucleus 
Interpeduncular nucleus 
Central gray 
Dorsal raphe nucleus 
Oculomotor nucleus 
Pontine nuclei 
Superior olivary complex 
Trigeminal motor nucleus 
Facial nucleus 
Mesencephalic trigeminal nucleus 
Locus coeruleus 
Vestibular nuclei 
Cochlear nuclei 
Spinal trigeminal nucleus 
Nucleus of the solitary tract 
Pontine reticular formation 
Medullary reticular formation 
Hypoglossal nucleus 
Inferior olivaly complex 
Cerebellum 
Deep nuclei 
Granule cell layer 
Purkinje cells 
Molecular layer 
** 
- 
** 
** 
*** 
*** 
*** 
*** 
- 
*** 
*** 
** 
** 
** 
* 
The number of symbols refers to the relative proportion of positive neurons, as assessed by P-Gal immunoperoxidase staining of brain sections from 5-week-old mice. p, No 
or very few positive cells; *, 120% positive cells; **, 20-50% positive cells; ***, >50% positive cells. 
Overall, the cell type specificity of the IE promoter in the 
mouse brain was highly consistent with known targets of HCMV 
infection in the human CNS (see Discussion) with one notable 
exception. Our analysis of normal brains failed to show IE pro- 
moter activity in astrocytes despite the fact that these cells are 
among the known infection targets in HCMV encephalitis in 
humans (Vogel, 1958; Wiley et al., 1986; Wiley and Nelson, 1988). 
Interestingly, a study by Poland et al. (1990) has shown that 
cultured astroglial cell types (including primary explants and sev- 
eral tumor-derived lines) vary greatly in their ability to express 
HCMV antigens and in their support of HCMV replication. In 
view of these observations, it occurred to us that astrocytes in- 
fected by HCMV in viva may have become permissive during the 
course of gliosis, the reactive astrocytosis process that typically 
accompanies diverse neurological insults, including viral infec- 
tions of the CNS. Gliosis is a common feature of HCMV infection 
in the brain (Haymaker et al., 1954; Wiley and Nelson, 1988; 
Vinters et al., 1989). Thus, we reasoned that changes in gene 
expression in activated astrocytes, exemplified by induction of 
GFAP (Eng and Ghirnikar, 1994), might lead to activation of the 
IE promoter and subsequent permissivity for HCMV infection. 
We tested this idea experimentally in the following way. A stab 
lesion was made unilaterally in the frontal cortex of anesthetized 
transgenic mice and nontransgenic littermate controls. The mice 
recovered without incident and were killed for brain histology at 
various time points during the ensuing course of gliosis and lesion 
repair. Immunohistochemical analysis of brain sections was per- 
formed using antibodies against P-Gal and GFAP, a standard marker 
to identify reactive astrocytes during gliosis. This experiment re- 
vealed a striking and prolonged induction of IE promoter activity in 
the cerebral cortex of lesioned HCMV-1 transgenic mice. The in- 
duction was not evident at 0 or 6 hr postlesion, but was first detected 
at 12 and 24 hr in a few cells scattered in and around the lesion site 
(data not shown). The number of cells with P-Gal-positive nuclei 
near the lesion increased dramatically over the next 2 d (3 d time 
point; Fig. U). Anti-GFAP antibody staining identified the cytoplas- 
mic processes of reactive astrocytes distributed in a pattern similar to 
that of the P-Gal-positive nuclei (in Fig. 3, compare B to A). At the 
6 d time point, numerous P-Gal-positive cells were observed around 
the lesion site (Fig. 3C) and, in addition, positive cells were scattered 
throughout the entire ipsilateral (lesioned side) cortex (Fig. 3C,E) 
and also in the underlying striatum (Fig. 30. Interestingly, none of 
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Figure 3. Induction of HCMV IE promoter activity in the ipsilateral cerebral cortex and caudate-putamen after a stab wound in the cortex. Enhanced HCMV 
IE promoter activity parallels the gliosis, as visualized by immunoperoxidase staining for P-Gal and GFAP, respectively. A, B, Lesion site after 3 d survival. The 
highly localized distribution of P-Gal-positive nuclei (A) closely matches that of GFAP-positive glial cells (B) around the lesion. C depicts the increase in HCMV 
IE promoter activity seen ipsilaterally 6 d after the lesion [open awow on the lesioned side &es)] compared with the contralateral, nonlesioned side (C@l of the 
same animal. Notice the broad distribution of P-Gal-positive nuclei throughout the ipsilateral cortex and underlying caudate-putamen (CPU; arrows), but not in 
the globus pallidus (GP; arrow/read). The lesion-induced increase in P-Gal and GFAP staining in the ipsilateral cerebral cortex seen after 6 d survival is depicted 
in panels E and G, respectively; the P-Gal and GFAP staining in the contralateral, control side, is shown in D and F, respectively. Arrowheads in D point to rare 
positive neuronal nuclei on the control side; arrows in E point to dramatically enlarged astrocytes where the P-Gal immunostaining spreads into the processes 
(see Fig. 2E for a higher magnification of such a cell). There is only very weak basal GFAP staining in cerebral cortex on the control side (arrowhead in F), 
whereas on the lesioned sides reactive astrocytes are distributed evenly throughout all cortical layers. H and I illustrate the increase in HCMV IE promoter 
activity in the caudate-putamen on the lesioned side (T) compared with the unlesioned side (H). See Figure 2G for identification of these cells as astrocytes. ac, 
Anterior commissure; Pir, piriform cortex. Scale bars: A-B and D-Z, 200 pm; C, 500 pm. 
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the animals tested showed changes in the ipsilateral hippocampus or 
in the contralateral (unlesioned side) hemisphere with regard to 
either P-Gal- or GFAP-positive cells. Thus, at all time points tested 
(up to 6 d), the contralateral hemisphere of the lesioned mice (Fig. 
3C,D,F,H) appeared much like the unlesioned controls (latter not 
shown). 
Immunofluorescent double-labeling analysis with anti-GFAP and 
anti-P-Gal antibodies revealed that the majority, if not all, of the cells 
showing inducible IE promoter activity in the lesioned brains were 
reactive astrocytes, strongly positive for GFAP (Fig. 2E-G). The few 
P-Gal-positive nuclei present in GFAP-negative cells in these sec- 
tions had the typical size and morphology of neuronal nuclei, and 
likely represented neurons that were already P-Gal-positive before 
lesioning. A similar proportion of P-Gal-positive neurons was also 
seen in the contralateral hemisphere and in unlesioned controls. The 
double-labeling analysis also revealed that reactive astrocytes were 
not entirely homogeneous with regard to IE promoter induction 
because a fraction of the GFAP-positive astrocytes remained P-Gal- 
negative. Near the lesion (cl mm), these P-Gal-negative astrocytes 
represented -20% of all GFAP-positive astrocytes. Their proportion 
increased to -35% in areas of the cortex distant from the lesion (>3 
mm). Finally, there was no evidence for the induction of IE promoter 
activity in other cell types, notably endothehal cells or microglial cells 
in the lesioned brains. 
DISCUSSION 
In the study presented here, we have shown that the HCMV 
major IE promoter (-524 to +13 segment) is active in rcstrictcd 
sites and cell types in brains of transgcnic mice. Cell types that 
were competent to activate the IE promoter included some en- 
dothelial cells, ependymal cells, choroid plexus cpithelia, and 
discrete neuron populations in the deep cortex, hippocampus, 
cerebellum, thalamus, brainstem, and olfactory bulb. The propor- 
tions of endothelial cells and neurons with activity were greater in 
neonatal than adult brains. Although the IE promoter was notably 
inactive in most astrocytes in the normal adult brain, it was 
inducible in reactive astrocytes during gliosis in response to a 
cortical lesion. Gliosis, an astrocytic response to diverse neuro- 
logical insults, is a typical finding in HCMV encephalitis (Hay- 
maker et al., 1954; Eng and Ghirnikar, 1994). The cell type- and 
differentiation status-dependent activity of the IE promoter doc- 
umented here is highly consistent with known features of HCMV 
infection permissivity in culture and in viva (Lathey et al., 1990; 
Poland et al., 1990; Fiala et al., 1993). In autopsied brain tissue 
from individuals dying of fatal infection, cytomegalic cells 
(HCMV-infected cells that are characteristically enlarged and 
contain Cowdry type A viral inclusion bodies) have been noted in 
endothelial cells, ependymal and choroid plexus epithelia, and in 
astrocytes and neurons (Haymaker et al., 1954; Klatt and Shibata, 
1988; Wiley and Nelson, 1988, 1993; Vinters et al., 1989; Fiala et 
al., 1993; Vinters and Ferreiro, 1993). Sites of infection frequently 
noted in congenital and adult HCMV encephalitis include lepto- 
meningeal blood vessels, choroid plexus, and ependymal and 
subependymal (subventricular) regions; less frequently, infection 
has also been observed in the granule cell layer of the cerebellum, 
caudate-putamen, pallidurn, thalamus, and olfactory bulb (Worth 
and Howard, 1950; Haymaker et al., 1954; Wiley et al., 1986; 
Vinters et al., 1989). Together with our previous work showing 
correlation between sites of IE promoter activity in transgenic 
mouse embryos and known target tissues of congenital HCMV 
infection in human fetuses (Koedood et al., 1995), the present 
analysis extends this correlation to specific cell types and regions 
in the neonatal and adult brain. The data provide strong evidence 
that cell type specificity of the IE promoter is conserved between 
humans and mice and that this promoter plays a major role in 
determining cellular permissivity for HCMV infection in humans. 
Although it has been long suspected that the interaction be- 
tween host cell transcription factors and the major IE promoter 
plays an important role in HCMV infection permissivity, gene 
transfection experiments with cultured cells have confused this 
issue by paradoxically suggesting that the IE promoter is highly 
active in most cell types. In contrast, we have observed restricted 
activity of the IE promoter in viva. More importantly, the in viva 
cell type specificity of the IE promoter correlates well with known 
targets of HCMV infection in humans. Based on this correlation, 
it appears that transgenic mice constitute a more relevant proba- 
tive system than transfected cultured cells for studying IE pro- 
moter regulation as it pertains to HCMV infections in viva. 
Among the cell types able to activate IE promoter transcription 
in the brain, endothelial cells represent key targets of HCMV 
infection with regard to encephalopathies because they maintain 
the tight junction blood-brain barrier, which normally blocks 
entry of virus into the CNS. Infected endothelial cells have been 
strongly implicated as major disseminators of virus during sys- 
temic HCMV infections (Vogel, 1958; Grefte et al., 1993; Wald- 
man et al., 1995). In AIDS patients, HCMV infection of endo- 
thclial cells is bclicvcd to facilitate entry and dissemination of 
HIV in the CNS by causing a breakdown in the blood-brain 
barrier and attracting HIV-infcctcd inflammatory cells (macro- 
phages and multinucleated giant cells) into the brain (Wiley and 
Nelson, 1993). Thereafter, HCMV and HIV may act synergisti- 
cally to cause particularly severe encephalopathies (Nelson et al., 
1988; Skolnik et al., 1988; Ho et al., 1990). Histopathological 
analysis of HCMV-infected brain tissue suggests that HCMV can 
spread from the leptomeninges into underlying tissue via micro- 
vasculature to cause focal subdural damage (frequently seen in 
AIDS patients with HCMV encephalitis), and also can spread 
from the brain ventricles in a ventriculofugal manner (from 
ependyma into adjacent subependymal regions) (Haymaker et al., 
1954; Wiley and Nelson, 1988; Vinters et al., 1989). Because a 
recent in vitro study suggests that efficient transmission of HCMV 
requires direct celhcell contact (Waldman et al., 1995) it seems 
likely that ventricular spread of HCMV infection may be pre- 
ceded by infection of the choroid plexus, where ventricular 
ependymal cells are uniquely juxtaposed to a rich bed of endo- 
thelial cells and choroid plexus epithelia. 
HCMV also has been implicated in other nervous system pa- 
thologics that involve destruction of blood-nerve or blood-brain 
barriers, including Guillain-Barre syndrome-like polyneuropa- 
thies that have been observed in previously healthy individuals 
after HCMV mononucleosis (Bale, 1984; Fiala et al., 1993), and 
Rasmussen’s encephalitis, a form of childhood epilepsy caused by 
autoimmune antibodies against glutamate receptors (Rogers et 
al., 1994; Jay et al., 1995; Twyman et al., 1995). HCMV DNA has 
been detected by polymerase chain reaction in brain tissue from 8 
of 10 patients with Rasmussen’s encephalitis (and in 0 of 5 
controls with other types of encephalitis), and has been postulated 
to be an important cofactor by causing chronic blood-brain bar- 
rier disruption that allows leakage of antiglutamate receptor an- 
tibodies into the brain (Jay et al., 1995). 
Several families of DNA-binding transcription factors, includ- 
ing CAMP response element binding, NFKB/rel, and retinoic acid 
receptor factors have been implicated in activation of the IE 
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promoter in various cell types (for review, see Ghazal and Nelson, 
1993). The delayed in viva induction that we have characterized in 
astrocytes likely represents dependence on de nova synthesis of 
transcription factors or on the relatively slow decay of a repressor. 
Given the similarity in induction kinetics for the IE and GFAP 
promoters in reactive astrocytes, it is possible that the two pro- 
moters are regulated via the same signal transduction pathway(s). 
Relevant signaling molecules may include interleukin and TGF-/3 
family cytokines that are known to be released in response to stab 
lesioning and to have effects on transcription of the GFAP pro- 
moter (Brenner, 1994). Interestingly, we have observed that the 
IE promoter is activated in cortical slice cultures of the HCMV- 
IE-ZucZ transgenic mice (unpublished data), indicating that ex- 
perimental approaches using organ and slice cultures may be 
useful for studying IE promoter regulation in response to growth 
factors and cytokines. 
In conclusion, this transgenic analysis provides compelling evi- 
dence that cell type-specific regulatory proteins that act on the IE 
promoter are significant determinants of HCMV infection speci- 
ficity in the brain. Expansion of potential infection targets by IE 
promoter induction as exemplified in reactive astrocytes is likely 
to play an important role in progression of HCMV encephalitis 
and in opportunistic infection strategies used by HCMV in other 
tissues as well. This transgenic system should facilitate identifica- 
tion of cellular transcription factors that repress or activate the IE 
promoter in viva and thereby affect permissivity for HCMV 
infection. 
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